SCHEMBL17100669

SCHEMBL17100669

c1ccc(-c2noc(N3CCN(CCN4CCOCC4)CC3)n2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 1/20 0.49
▸ KCNH2 Q12809 1/20 0.49
▸ ALDH1A1 P00352 4/20 0.48
▸ MAPT P10636 3/20 0.48
▸ CASP1 P29466 2/20 0.48
▸ LMNA P02545 2/20 0.48
▸ CASP7 P55210 1/20 0.48
▸ HTT P42858 2/20 0.48
▸ FAAH O00519 1/20 0.47
▸ NPC1 O15118 2/20 0.47
▸ RAB9A P51151 2/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ TP53 P04637 2/20 0.46
▸ TSHR P16473 2/20 0.46
▸ TLR9 Q9NR96 1/20 0.46
▸ ALOX15 P16050 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ USP2 O75604 1/20 0.46
▸ GLA P06280 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27814281 0.90 HTT (0.58) MAPTCASP1LMNAHTTFAAH
SCHEMBL17100792 0.85 ADORA2A (0.47) ALDH1A1MAPTCASP1HTTTP53
SCHEMBL17100583 0.83 CYP2D6 (0.71) CYP2D6KCNH2ALDH1A1MAPTCASP1
SCHEMBL17100625 0.83 CYP2D6 (0.46) CYP2D6KCNH2ALDH1A1MAPTCASP1
SCHEMBL17100809 0.80 ALDH1A1 (0.54) CYP2D6KCNH2ALDH1A1MAPTLMNA
SCHEMBL17100762 0.79 CYP2D6 (0.57) CYP2D6KCNH2ALDH1A1MAPTCASP1
SCHEMBL17100616 0.78 LMNA (0.67) CYP2D6KCNH2ALDH1A1MAPTCASP1
SCHEMBL17115008 0.78 KMT2A (0.55) CYP2D6KCNH2ALDH1A1MAPTCASP1
SCHEMBL17100673 0.77 ALDH1A1 (0.57) CYP2D6KCNH2ALDH1A1MAPTLMNA
SCHEMBL17100581 0.77 HTR1A (0.48) CYP2D6KCNH2ALDH1A1MAPTCASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 — — US claimed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 — — US claimed
EP-3119774-A1 OXADIAZOLE COMPOUNDS reMynd NV (BE) 2017-01-25 — — EP claimed
WO-2015140130-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2015-09-24 — — WO claimed
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 — — US disclosed
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 — — US disclosed
US-10562869-B2 Oxadiazole compounds REMYND NV (BE) 2020-02-18 — — US disclosed
US-10562869-B2 Oxadiazole compounds REMYND NV (BE) 2020-02-18 — — US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 — — US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 — — US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 — — US disclosed
EP-3119774-A1 OXADIAZOLE COMPOUNDS reMynd NV (BE) 2017-01-25 — — EP disclosed
WO-2015140130-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2015-09-24 — — WO disclosed
WO-2015140130-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2015-09-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10562869-B2 Oxadiazole compounds OXA1L, PSEN1, MAPT CYP2D6 739/4885KCNH2 4581/4885ALDH1A1 482/4885
US-20200140400-A1 OXADIAZOLE COMPOUNDS OXA1L, PSEN1, MAPT CYP2D6 873/4885KCNH2 4624/4885ALDH1A1 561/4885
US-20170073319-A1 OXADIAZOLE COMPOUNDS OXA1L, PSEN1, MAPT CYP2D6 739/4885KCNH2 4581/4885ALDH1A1 482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback